Milan

• A Phase 2 Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejecti … Ended
  2023-508737-13-00 4 2024-08-08 chronic heart failure
• Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis Ended
  2023-508679-34-00 4 2024-07-30 Ulcerative Colitis
• A Phase 3, Placebo-controlled, Cross-over Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adu … Ended
  2023-507268-37-00 5 2024-07-29 Hereditary Angioedema
• REIMAGINE 1: A research study to see how much CagriSema lowers blood sugar and body weight compared to placebo in people with type 2 diabete … Ended
  2022-502677-42-00 5 2024-07-24 Type 2 diabetes
• A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the tr … Ended
  2023-506185-31-00 10 2024-07-18 Idiopathic pulmonary fibrosis (IPF)
• “A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis” Ended
  2023-503289-22-00 4 2024-07-05 Relapsing Multiple Sclerosis
• Phase 2b study to investigate the safety and efficacy of TIN816 in SA-AKI Ended
  2023-505903-22-00 4 2024-07-02 Sepsis associated acute kidney injury
• A study to assess and compare safety and tolerability of 3 months treatment with salbutamol administered via MDI containing propellant HFA-1 … Ended
  2023-509001-76-00 5 2024-07-01 Asthma
• A study to test long-term treatment with spesolimab in people with a skin condition disease called hidradenitis suppurativa (HS) who took pa … Ended
  2023-508377-82-00 10 2024-06-27 Hidradenitis Suppurativa (HS)
• A study to evaluate the efficacy and safety of subcutaneous amlitelimab in participants aged 12 years and older with moderate-to-severe atop … Ended
  2023-506558-20-00 5 2024-06-26 Dermatitis atopic
• An open-label study for participants who are non-responders at the end of treatment assessment on the VRDN-001-101 and VRDN-001-301 pivotal … Ended
  2023-507350-33-00 5 2024-06-25 Thyroid eye disease
• A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i … Ended
  2023-506696-10-00 5 2024-06-18 Non-Small Cell Lung Cancer
• A Proof-of-Concept study to assess the efficacy, safety and tolerability of itepekimab (anti-IL-33 mAb) in participants with non-cystic fibr … Ended
  2023-508663-70-00 4 2024-06-18 Bronchiectasis
• A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy. Ended
  2023-504892-25-00 5 2024-06-14 Narcolepsy
• A Two-Part Study to Assess the Effectiveness, Safety, and Blood Levels of Repeat Doses of Inhaled ETD001 in People with Cystic Fibrosis Ended
  2023-504092-25-00 4 2024-06-04 Cystic Fibrosis
• AMX0035 and Progressive Supranuclear Palsy Ended
  2023-505893-14-00 5 2024-06-04 Progressive Supranuclear Palsy
• Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or … Ended
  2023-508884-59-00 5 2024-06-03 Hemophilia A or Hemophilia B
• A Phase IIb, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Po … Ended
  2022-500410-26-01 4 2024-05-27 Cystic Fibrosis
• A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma Ended
  2023-507324-23-00 4 2024-05-22 recurrent or persistent uterine serous carcinoma
• A Phase 1/2 Study of TAS3351 in Patients with Advanced Non-Small Cell Lung Cancer and EGFR Mutations Ended
  2022-502595-23-00 7 2024-05-21 Patients with locally advanced or metastatic non-small cell lung cance
• [68Ga]Ga-PentixaFor-PET imaging for staging of marginal zone lymphoma Ended
  2022-500918-25-00 5 2024-05-20 Marginal Zone Lymphoma
• A study to evaluate safety and efficacy of two different concentrations of a new formulation of Recombinant Human Nerve Growth Factor (rhNGF … Ended
  2023-507561-26-00 4 2024-05-17 Dry Eye
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis Ended
  2023-506655-19-00 4 2024-05-16 Ulcerative Colitis (UC)
• Tirzepatide, a new drug for type 2 diabetes mellitus and obesity, as a possible treatment to modify the clinical evolution of Wolfram syndro … Ended
  2024-514909-64-00 4 2024-05-16 Wolfram syndrome type 1

Showing 1,921–1,944 of 2,361 trials